Are MASI, ACLX, GLDD Obtaining Fair Deals for their Shareholders?

Rhea-AI Summary

{"summary":"","positive":[],"negative":[],"faq":[]}

News Market Reaction – ACLX

-0.02%

1 alert

-0.02% News Effect

On the day this news was published, ACLX declined 0.02%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

MASI deal price: $180.00 per share ACLX cash consideration: $115.00 per share ACLX CVR: $5.00 per share +1 more

4 metrics

MASI deal price $180.00 per share Masimo sale consideration to Danaher

ACLX cash consideration $115.00 per share Arcellx sale consideration to Gilead Sciences

ACLX CVR $5.00 per share Contingent value right upon achievement of milestones

GLDD deal price $17.00 per share Great Lakes Dredge & Dock sale consideration to Saltchuk Resources

Market Reality Check

Price: $114.33 Vol: Volume 251,278 vs 20-day ...

low vol

$114.33 Last Close

Volume Volume 251,278 vs 20-day average 4,651,117 (relative volume 0.05x) shows muted trading. low

Technical Price $114.39 is above 200-day MA at $76.31, reflecting a pre-existing uptrend into the deal.

Peers on Argus

ACLX was roughly flat (-0.02%) while peers like ARWR (-1.73%), ACAD (-2.09%), an...

ACLX was roughly flat (-0.02%) while peers like ARWR (-1.73%), ACAD (-2.09%), and KRYS (-1.8%) moved more sharply, indicating this legal-investigation headline was stock-specific rather than a sector rotation.

Historical Context

5 past events · Latest: Mar 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Deal fairness inquiry	Neutral	+0.0%	Law firm announced investigation into fairness of ACLX shareholder deal terms.
Feb 23	Acquisition announcement	Positive	+77.4%	Gilead agreed to acquire Arcellx for cash plus CVR at a premium.
Feb 04	Clinical data update	Positive	-0.1%	Preclinical data showed favorable target specificity and safety profile for anito‑cel.
Jan 21	Conference presentations	Positive	-0.4%	Tandem meeting abstracts highlighted D‑Domain platform data and access modeling.
Dec 06	Pivotal trial results	Positive	+6.5%	Updated Phase 2 iMMagine‑1 data showed high response rates and solid survival.

Pattern Detected

Major value-defining events such as the announced Gilead acquisition triggered strong positive reactions, while scientific updates and conference-related news sometimes saw slight negative or flat moves despite positive content.

Recent Company History

Over the past several months, Arcellx has transitioned from positive clinical momentum to a pending acquisition. A Feb 23, 2026 deal announcement with Gilead for $115 cash + $5 CVR drove a 77.43% move. Earlier, strong iMMagine‑1 Phase 2 data on Dec 6, 2025 lifted shares 6.5%, while subsequent Tandem meeting updates in early 2026 had slightly negative or flat price reactions. A prior law-firm “fair deal” notice on Mar 3, 2026 saw a 0% move, similar to today’s muted response.

Market Pulse Summary

This announcement highlights a law firm’s review of whether ACLX’s agreed sale terms—$115 per share ...

Analysis

This announcement highlights a law firm’s review of whether ACLX’s agreed sale terms—$115 per share in cash plus a $5 CVR—adequately compensate shareholders, a theme echoed in a prior March 2026 notice. Historically, the major re-pricing occurred on the initial Gilead deal announcement, while subsequent legal and process updates produced muted moves. Investors tracking this situation often focus on deal progress in SEC filings, prior clinical strength, and any competing bids or board recommendations.

Key Terms

contingent value right, federal securities laws, fiduciary duties

3 terms

contingent value right financial

"plus one contingent value right of $5.00 per share upon the achievement..."

A contingent value right is a special security that gives its holder the right to receive one or more future payments only if specified events happen, such as a product reaching a sales target or getting regulatory approval. It matters to investors because it offers potential extra payout tied to uncertain outcomes—like a bet that a project will succeed—so it can add upside to a deal while also carrying extra risk and valuation uncertainty.

federal securities laws regulatory

"potential violations of the federal securities laws and/or breaches of fiduciary..."

Federal securities laws are the set of national rules that require companies and market participants to provide accurate information, prohibit deceptive practices, and ensure fair trading of stocks and bonds. Think of them as the rules of the road for financial markets: they help investors make informed choices by mandating disclosures and punishing fraud, which reduces risk and builds trust in the safety and reliability of investments.

fiduciary duties regulatory

"and/or breaches of fiduciary duties to shareholders relating to: Masimo..."

Fiduciary duties are the legal and ethical responsibilities that company directors, officers, or financial advisors have to put shareholders’ interests ahead of their own, acting with honesty, care, and loyalty. Think of it like a guardian managing someone’s money: choices must prioritize the owner’s benefit, avoid conflicts, and be made with prudent judgment; investors rely on these duties to ensure decisions aren’t self‑serving and to provide grounds for legal action if abused.

AI-generated analysis. Not financial advice.

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

The proposed transactions may contain terms that could limit superior competing offers.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

NEW YORK, March 16, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Masimo Corporation (NASDAQ: MASI)'s sale to Danaher Corporation for $180.00 per share in cash. If you are a Masimo shareholder, click here to learn more about your legal rights and options.

Arcellx, Inc. (NASDAQ: ACLX)'s sale to Gilead Sciences, Inc. for $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones. If you are an Arcellx shareholder, click here to learn more about your legal rights and options.

Great Lakes Dredge & Dock Corporation (NASDAQ: GLDD)'s sale to Saltchuk Resources, Inc. for $17.00 per share in cash. If you are a Great Lakes shareholder, click here to learn more about your rights and options.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/are-masi-aclx-gldd-obtaining-fair-deals-for-their-shareholders-302714560.html

SOURCE Halper Sadeh LLP